



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 15TH MAY 2019 AT
12.00pm**

**IN SEMINAR ROOM 2, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT (Acting chair)
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust
Dr L Rogan (LR)	Associate Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Dr K Burch (KB)	Consultant Microbiologist ELHT

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician EL CCG
Nicola Everett	Clinical Procurement Specialist Nurse
Sophie Harrison	Pharmacy Technician, NHS BwD CCG

2019/053: APOLOGIES:

Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr T Mackenzie (TM)	GP, EL CCG
Mr A Gray (AG)	Clinical Pharmacist, ELHT

2019/054: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2019/055: MINUTES OF MARCH MEETING:

Accepted as a correct record.

2019/056: MATTERS ARISING:

2019/027: Antihistamines Prescribing Policy – a Position Statement has been prepared for prescribing of antihistamines and nasal sprays for mild to moderate hayfever and allergic rhinitis. Accepted for use in EL Health Economy.

Resolved: Antihistamine Position Statement accepted for use in ELHE

2019/025: ELHE: Respiratory Guidelines – Updated: COPD Guideline - updated from previous version with some additional minor comments. Further comments: AirFluSal MDI (not licensed for COPD) to be replaced by Symbicort MDI, Fobumix Easyhaler to be removed, Trelegy Ellipta to be equal option with combination of two dry powder inhalers. Amendments to be included and final version brought back to next meeting.

2019/040: Dry Eye Products Review Including New Product Requests – VisuXl® and Systane Balance® - formulary summary and choices has been updated. It was suggested that more items should be considered as self-care with the exception of severe dry eye. Xailin HA (sodium hyaluronate 0.2%) has been requested for addition by ophthalmology. To check with ophthalmology whether this would replace Hyloforte or Evolve. It was suggested that sodium hyaluronate 0.2% be added generically to facilitate use of most cost effective product.

2019/041: Lutein & Oral Antioxidant Vitamin Supplements For Eye Conditions – awaiting comments from ophthalmology.

2019/044: LMMG Recommendations (From Feb LMMG)

Out of Area Prescribing Position Statement – adapted version to next meeting.

Choice of direct-acting oral anticoagulant (DOAC) for stroke prevention in non-valvular atrial fibrillation (AF) – updated, - comments shared with LSC Meds Leads.

Restless Legs Syndrome in Adults in primary Care (version 1.2) – update - comments sent to LMMG.

2019/047: Prescribing For Clinical Need Policy – latest version was shared at last meeting. LMMG are updating, when finalised will go to Joint Committee of CCG's for ratification.

Deferred item

2019/042: WOUND CARE FORMULARY - UPDATED

The wound care formulary has been reviewed by the Lancashire Cluster of East Lancs, Blackpool and Lancashire Teaching trusts to update and align products. There are also some national product recommendations that have been included. The lymphoedema, compression and tissue viability specialist products will be in a separate section. More updates will be made as national guidance extends to more products.

Resolved: Wound Care Formulary - Updated accepted for use in ELHE.

2019/057: NEW MEDICINES / UNLICENSED REQUEST RALOXIFENE AND SULINDAC

Raloxifene and Sulindac requested by Mrs Salaman, Consultant Colorectal Surgeon, for treatment of desmoid tumour, a rare condition, for an individual patient. It has been advised by a specialist from St Marks, in London. ELMMB approved the use by hospital specialist for this patient as an exception and suggest that an IFR should be completed if treatment ongoing.

Resolved: Raloxifene and Sulindac approved as an exception for a patient with desmoid tumour.
Traffic light: Red (for desmoid tumour)

2019/058: UNLICENSED MEDICINES REQUEST – ALICAFORSEN ENEMA RESUBMISSION

Requested by Dr Collum, Consultant Gastroenterologist, for treatment of refractory pouchitis in a small number of patients. Small studies have demonstrated benefit for this novel treatment. It is a six week course that can be administered at home, reducing hospital visits compared to infliximab treatment and avoiding surgery. A course of treatment is £1500 via a named patient scheme.

Approved for use by Consultant gastroenterologist only for a small number of refractory patients. Funding will remain responsibility of the directorate.

It was suggested to advise consultant to submit a request to LMMG for consideration of an evidence review.

Resolved: Alicaforsen Enema approved for use by Consultant Gastroenterologist only in refractory patients only.
Traffic Light: RED

2019/059: NEW MEDICINE REQUEST – CICLOSPORIN (VERKAZIA®) EYE DROPS

Request referred to LMMG and is now on their work plan to review.

2019/060: LMMG CONSULTATIONS (for May LMMG)

For information only – response date passed.

Primary Care Good Prescribing Guidelines - updated
Lithium Shared Care Guideline – updated

2019/061: LMMG CONSULTATIONS (for June LMMG)

Melatonin (Slenyto®) New Medicine assessment – this prolonged released tablet is licensed in children for insomnia with Autism Spectrum Disorder and /or Smith-Magenis syndrome. Concerns expressed that the licence doesn't cover the indications it would be used for if it replaced Circadin®. The evidence for use also does not include the indications required for local use.

Prasterone (Intarosa®) New medicine assessment – recommended black for vulvar & vaginal atrophy in post-menopausal women with symptoms. ELMMB support this recommendation.

Resolved: Comments to be sent to LMMG

2019/062: LMMG Recommendations (From March LMMG)

Ospemifene New Medicine Assessment - recommended black for vulvar & vaginal atrophy in post-menopausal women with symptoms. Accepted as written for ELHE.

Traffic Light BLACK

Guidance for Prescribing second generation Long Acting Anti-psychotic Injections (LCFT document) – acknowledged by ELMMB.

2019/063: LMMG Recommendations (From April LMMG)

Fortacin New Medicines recommendation - recommended black for primary premature ejaculation. Accepted as written for ELHE.

Traffic Light BLACK

Transanal Irrigation Systems Position Statement – updated – accepted as written for use in ELHE. Aquaflush® Lite, Compact & Quick to be added to formulary.

FreeStyle Libre® update – the joint committee of CCGs for Lancashire have adopted the national criteria and retained existing local criteria for use in children. A specialist clinician responsible for patients diabetes care must determine patient's eligibility and provide device and sensors for first two weeks. Ongoing supplies of sensors can be from GP's. - traffic light is changed to Amber.

Traffic Light: AMBER

2019/064: FORMULARY UPDATES

Tenofovir – change from Amber to red as it is commissioned by NHS England.

Traffic Light: Red

Diltiazem MR capsules – the trust is changing the brand used from Slozem to Viazem, which is more cost effective. Clear communication will be required on discharge when patients are swapped to Viazem.

Traffic Light: Green

Tranexamic acid injection for topical use – proposal made to change traffic light green as it is often district nurses who are caring for patients who may need this treatment. Response from specialist palliative care awaited.

Resolved: Formulary to be updated as above

2019/065: ANTIMICROBIAL GUIDELINES – SECONDARY CARE

Urinary tract guidelines – updated – UTI (lower), UTI (recurrent) & Pylonephritis (acute) updated in line with NICE guidance by antimicrobial stewardship group, with local products included. Dipstick testing should not be in routine use in hospital to diagnose UTIs.

Diabetic Foot Infection guideline – updated – in line with NICE guidance by antimicrobial stewardship group.

Resolved: Urinary tract & Diabetic foot infection Secondary care Guideline updates accepted.

2019/066: ANTIMICROBIAL GUIDELINES – PRIMARY CARE

Otitis media (acute) guideline – updated in line with NICE by antimicrobial stewardship group.

Prostatitis (acute) guideline - updated in line with NICE by antimicrobial stewardship group.

Resolved: Otitis media & Prostatitis Primary care Guideline updates accepted.

2019/067: UTI ASSESSMENT FORM FOR CARE HOMES

Form developed to support care homes when contacting GP's with suspected UTIs. Care home staff will receive training on its use. Form acknowledged by ELMMB

Resolved: UTI Assessment form acknowledged.

2019/068: NICE RECOMMENDATIONS (from Mar)

Benralizumab for treating severe eosinophilic asthma [TA565] is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Cochlear implants for children and adults with severe to profound deafness [TA566] is recommended as an option by NICE. Approved in line with NICE.

Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (TA567) is recommended as an option by NICE. Approved in line with NICE.

Cancer Drugs Fund

Traffic Light: RED

Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)

Traffic Light: BLACK

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)

Traffic Light: BLACK

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned

Traffic Light: GREEN

2019/069: NICE RECOMMENDATIONS (from April)

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA573) is recommended as an option by NICE. Approved in line with NICE. Cancer Drugs Fund **Traffic Light: RED**

Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574) is recommended as an option by NICE. Approved in line with NICE. CCG Commissioned Blueteq form required **Traffic Light: RED**

Tildrakizumab for treating moderate to severe plaque psoriasis (TA575) is recommended as an option by NICE. Approved in line with NICE. CCG Commissioned Blueteq form required **Traffic Light: RED**

Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576) **Traffic Light: BLACK**

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577) is recommended as an option by NICE. Approved in line with NICE. NHS England Commissioned **Traffic Light: RED**

STANDING ITEMS

2019/070: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – March 2019

Minutes acknowledged

2019/071: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – April 2019

Minutes acknowledged

2019/072: FOR ACTION/INFORMATION: LANCASHIRE CARE FT D & T MINUTES – March 2019

Minutes acknowledged

DATE OF NEXT MEETING – Wednesday 19th June 2019 12.00noon, Seminar Room 2, Learning & Development Centre, RBH

Dates for 2019: All 3rd Wednesday of the month starting at 12 noon

19th June

17th July

21st August

18th September

16th October

20th November

18th December

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 15TH MAY 2019

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/025	ELHE: Respiratory Guidelines – Updated COPD guideline – to incorporate latest comments	JV	May 19
2019/040	Dry Eye Drops Including New Product Requests – VisuXL®, Systane Balance® - to incorporate latest comments	JV	May 19
2019/041	Lutein & Oral Antioxidant Vitamin Supplements For Eye Conditions – refer to ophthalmologist specialising in macular degeneration for comments	CW	Apr 19
2019/044	LMMG Recommendations (from Feb LMMG) – Out of area prescribing Position Statement – LR to adapt for ELHE	LR/JV	Apr 19
2019/064	Formulary Updates – Tranexamic acid – awaiting palliative care response	SJ / VG	May 19